Cost-effectiveness of new pneumococcal conjugate vaccines in Turkey: a decision analytical model
Open Access
- 9 November 2012
- journal article
- Published by Springer Science and Business Media LLC in BMC Health Services Research
- Vol. 12 (1), 386
- https://doi.org/10.1186/1472-6963-12-386
Abstract
Background: Streptococcus pneumoniaeinfections, which place a considerable burden on healthcare resources, can be reduced in a cost-effective manner using a 7-valent pneumococcal conjugate vaccine (PCV-7). We compare the cost effectiveness of a 13-valent PCV (PCV-13) and a 10-valent pneumococcal non-typeableHaemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) with that of PCV-7 in Turkey.Methods: A cost-utility analysis was conducted and a decision analytical model was used to estimate the proportion of the Turkish population <10 years old that would experience 10 mutually exclusive outcomes over the course of 1 year from a perspective of a healthcare system. Model outcomes were adjusted according to the population demographics and region-specific serotype distribution in Turkey. Health outcomes and direct healthcare costs were simulated for PCV-7, PCV-13 and PHiD-CV.Results: PCV-13 and PHiD-CV are projected to have a substantial impact on pneumococcal disease in Turkey versus PCV-7, with 2,223 and 3,156 quality-adjusted life years (QALYs) and 2,146 and 2,081 life years, respectively, being saved under a 3+1 schedule. Projections of direct medical costs showed that a PHiD-CV vaccination programme would provide the greatest cost savings, offering additional savings of US$11,718,813 versus PCV-7 and US$8,235,010 versus PCV-13. Probabilistic sensitivity analysis showed that PHiD-CV dominated PCV-13 in terms of QALYs gained and cost savings in 58.3% of simulations.Conclusion: Under the modeled conditions, PHiD-CV would provide the most cost-effective intervention for reducing pneumococcal disease in Turkish children.This publication has 48 references indexed in Scilit:
- Serotypes of Streptococcus pneumoniae Isolates from Children with Invasive Pneumococcal Disease in Turkey: Baseline Evaluation of the Introduction of the Pneumococcal Conjugate Vaccine NationwideClinical and Vaccine Immunology, 2011
- Economic evaluation of pneumococcal conjugate vaccination in The GambiaBMC Infectious Diseases, 2010
- Pharmacoeconomic evaluation of 10- and 13-valent pneumococcal conjugate vaccinesVaccine, 2010
- Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal diseaseBMC Infectious Diseases, 2010
- Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: A new simulation modelClinical Therapeutics, 2009
- How to compare the efficacy of conjugate vaccines to prevent acute otitis media?Vaccine, 2009
- Has the licensing of respiratory quinolones for adults and the 7-valent pneumococcal conjugate vaccine (PCV-7) for children had herd effects with respect to antimicrobial non-susceptibility in invasive Streptococcus pneumoniae?Journal of Antimicrobial Chemotherapy, 2008
- Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control studyThe Lancet, 2006
- Efficacy of pneumococcal conjugate vaccines and their effect on carriage and antimicrobial resistanceThe Lancet Infectious Diseases, 2001
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaThe New England Journal of Medicine, 2001